CCEA approves proposal for strengthening drug regulatory

Image
Press Trust of India New Delhi
Last Updated : Aug 12 2015 | 9:57 PM IST
To facilitate domestic manufacture of quality medical products, the Cabinet Committee on Economic Affairs (CCEA) today approved a proposal for strengthening and upgrading the drug regulatory system both at the Central and state level.
The upgradation and strengthening of the system will also include setting up of new laboratories and training academy for regulatory and drug testing officials.
The CCEA chaired by Prime Minister Narendra Modi approved the proposal for strengthening the drug regulatory system at a total cost of Rs 1750 crore which will be spread over a period of three years.
"Out of the total amount of Rs 1750 crore, Rs 900 crore will be spent on strengthening central structures and Rs 850 crore will be made available to the state governments after signing a Memorandum of Understanding," an official statement said.
The up-gradation will include provision of additional equipment and manpower in existing drug testing laboratories, setting up of new laboratories for testing drugs, medical devices and cosmetics and making mobile drug testing laboratories available amongst others.
India is one of the largest manufacturers of drugs and exports pharmaceutical products to over 200 countries and economies.
"The implementation of the scheme will facilitate domestic manufacture of quality medical products and help establish a robust industry in the field of medical devices, biologicals and other areas. The common training programmes for regulatory and laboratory staff will also help in evolving uniform practices throughout the country," the statement said.
The upgradation will also include creation of additional manpower for regulatory structures, including for new and emerging areas such as stem cell, regenerative medicine, biologicals and medical devices in addition to drugs.
"The upgradation will also introduce organisation wide e-governance and information technology enabled and online services and setting up a training academy for regulatory and drug testing officials of both the central and state governments," the statement said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 12 2015 | 9:57 PM IST

Next Story